A Phase III, Randomized, Multicenter, Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients with Extensive Disease (Stage IV) Small-Cell Lung Cancer (SCLC)
Study of Drug in Combination with Traditional Chemotherapy for Patients with Stage IV Small-Cell Lung Cancer (SCLC)
Sponsor: AstraZeneca
Enrolling: Male and Female Patients
IRB Number: AAAR2668
Contact: Catherine Shu, MD: 212-305-3997 / cas2145@cumc.columbia.edu
Additional Study Information: This trial will look at how the study drug will work in combination with traditional chemotherapy at treating extensive-stage small cell lung cancer in the first-line setting. The study will also determine if these drugs cause any side effects compared to traditional chemotherapy alone. The study drug is Durvalumab by itself or with Tremelimumab. Both Tremelimumab and Durvalumab are antibodies (proteins produced by the body's defense system). These drugs may boost the ability of your immune system to detect and fight cancer. They do this by targeting signals that would stop the body's immune system from killing the cancer. Each drug blocks a different signal and by blocking these signals, the immune cells will once again be able to eliminate or slow down cancer growth.
This study is closed
Catherine Shu, MD
Do You Qualify?
Are you 18 years or older? Yes No
Have you received prior treatment for SCLC? Yes No
Do you have a history of autoimmune disease (such as colitis, Crohn's disease, lupus)? Yes No
Are you fully active or able to walk, care for yourself, and do light physical activities like light housework or office work? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Catherine Shu, MD